Evidence of Haloperidol Absorption After Topical Administration

Early Phase 1

Withdrawn

• Conditions: Nausea; Vomiting
• Interventions: Drug: Placebo; Drug: Haloperidol

• Registration Number: NCT01684969
• Lead Sponsor: Eric E. Prommer

Brief Summary

This will be a blinded study to compare the absorption of topical haloperidol with placebo

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-03-19
• Study First Submitted QC: 2012-09-10
• Study First Posted: 2012-09-13
• Primary Completion: 2013-05
• Study Completion: 2013-05
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-16
• Last Update Posted: 2016-03-17

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
intravenous haloperidol	Haloperidol	intravenous haloperidol pharmacokinetics

Primary Outcome Measures

Name	Time	Method
To measure the pharmacokinetics levels of haloperidol after topical administration compared with intravenous administration.	baseline to 240 minutes after administration.	Measuring either the presence of absence of haloperidol